Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study [0.03%]
流感患者的药物基因组标记物及大环内酯类药物的安全性：前瞻性研究的新见解
A A Skryabina,V V Nikiforov,M Z Shakhmardanov et al.
A A Skryabina et al.
Background: Macrolides are widely used antibiotics, but adverse drug reactions (ADRs), particularly in genetically predisposed individuals, can compromise their safety. This study examines the impact of pharmacogenetic ma...
Pharmacogenomic curriculum in Australian medical schools: a content analysis study [0.03%]
澳大利亚医学院药物基因组学课程的内容分析研究
Jade Thomas,Faith R Yong,Natalia Kryzyaniak et al.
Jade Thomas et al.
Aims: To ascertain and describe pharmacogenomic concepts included in the intended curriculum of accredited Australian medical schools. Methods: ...
CYP2C19 and CES1 gene variants affecting clopidogrel metabolism in a South Asian population from Sri Lanka [0.03%]
影响氯吡格雷代谢的CYP2C19和CES1基因变异体在来自斯里兰卡的南亚人群中的作用
Priyanga Ranasinghe,Pulasthi B Gunarathna,Hajanthy Jeyapragasam et al.
Priyanga Ranasinghe et al.
Aims: Clopidogrel exhibits substantial variability in therapeutic response, largely contributed by genetic factors. The pharmacogenomic variants data on clopidogrel metabolism in South Asians have been sparsely studied. T...
Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review [0.03%]
多替拉韦药代动力学的遗传变异及其与安全性和有效性结果的关系：系统性综述
Lisanne A H Bevers,Rebecca L Jensen,Andrew Owen et al.
Lisanne A H Bevers et al.
Background: Dolutegravir (DTG) is an antiviral agent used for the treatment of HIV, however, there is uncertainty over the influence of genetic variation on DTG exposure, and whether it has clinical implications for the e...
Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer? [0.03%]
CYP2D6基因型是否影响阿片酊的剂量、药动学、镇痛作用和不良反应？
Aaron K Wong,Sara Vogrin,Pal Klepstad et al.
Aaron K Wong et al.
Aims: To examine the associations between CYP2D6 and CYP3A4 polymorphisms, plasma oxycodone and metabolite concentrations, and oxycodone response (dose, pain scores, and adverse effects) in people with pain from advanced ...
Multicenter Study
Pharmacogenomics. 2024;25(14-15):579-586. DOI:10.1080/14622416.2024.2430161 2024
Effect of UGT1A6 and UGT2B7 polymorphisms on the valproic acid serum concentration and drug-induced liver injury [0.03%]
UGT1A6和UGT2B7多态性对丙戊酸血药浓度及药物性肝损伤的影响
Mengchen Yu,Yan Zhao,Fan Zhou et al.
Mengchen Yu et al.
Aim: Valproic acid (VPA) is a classic broad-spectrum antiepileptic drug, with significant pharmacokinetic variability. Genetic polymorphisms contribute to this variability, influencing both VPA trough serum concentration (VPA concentration)...
Advancing pharmacogenomics research: automated extraction of insights from PubMed using SpaCy NLP framework [0.03%]
利用SpaCy自然语言处理框架从PubMed中自动提取药理基因组学研究进展和见解
Esther Camilo Dos Reis,Santiago Caneppa,Pedro Vasconcelos et al.
Esther Camilo Dos Reis et al.
This paper presents a methodology for automatically extracting insights from PubMed articles using a Natural Language Processing (NLP) framework. Our approach, leveraging advanced NLP techniques and Named Entity Recognition (NER), is crucia...
Impact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study [0.03%]
基因变异对乳腺癌大手术患者芬太尼代谢的影响：候选基因关联研究
Shathish Kumar,Kesavan Ramasamy,Harivenkatesh Natarajan et al.
Shathish Kumar et al.
Aim: The study aimed to examine the association of two selected candidate SNPs rs2242480 (CYP3A4) and rs1045642 (ABCB1) with metabolic ratio of plasma norfentanyl to fentanyl concentrations in patients undergoing major br...
Hydroxychloroquine-induced acute generalized exanthematous pustulosis with HLA-typing [0.03%]
羟氯喹致急性广泛性发疹性脓疱病合HLA分型
Qiaoli Zheng,Na Jin,Hao Cheng
Qiaoli Zheng
Acute generalized exanthematous pustulosis (AGEP) is a rare drug reaction characterized by numerous pustules on an erythematous base. In some cases, hydroxychloroquine (HCQ) can cause AGEP. There is an association between HLA genes and AGEP...
PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar [0.03%]
过氧化物酶体增殖激活受体基因多态性rs1800234对吉贝齐疗效的影响为剂量依赖型相关关系
Zhaoxu Geng,Yuanting Zheng,Qian Li et al.
Zhaoxu Geng et al.
Background: Our objective was to explore the pharmacogenetic impact of three known functional variants in drug target genes and determine whether they can explain the inter-individual variation in therapeutic response. ...
Randomized Controlled Trial
Pharmacogenomics. 2024;25(14-15):605-610. DOI:10.1080/14622416.2024.2430163 2024